Børsen
Novo Nordisk’s semaglutide shows no statistically significant effect in trials against Alzheimer’s. The stock dropped significantly on Monday, but analysts call it an overreaction.
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?